.. 
 



   

 
   
 !"

#       (Neuroscience of Psychoative Substance Use and

Dependence) <="
#> ? @

A BCD #E 2547 (World Health
Organization,2004)R#>ST"
@
!"U@?V"B@B!W AB V
  "ABDABRX=
D

  @  B?D@ #D"#D
RB
D # @

RU@
10 #E"?@BW AB
  DA AS#  
(neuroimaging technique) "RB
\ V# @

D X=
"
B
R
BU V@
#>#]A"!WR   ""
 

B
@
BB
 AB

AAB VDABR"D ^ _
D 
 @B
DD"#V@  
B
B X  #
  @
  #>AB? # U  !W 
/#>aa
!"
BB#]
AB? # 
@
D B "D B@
B RU@ #
@a@#> ?D
A@B@D@@?V#b
V
R  !RB@
 !B@
 "D @W  #A W
="
@   #>W
#]
@
 B

 B ABA  D  
<="
 #W R?V T
 
  U@D!"A ADB
a
B cW@<="
<R#\RB@?DBV 
ACCDd=TB
#>aD@WB  @
) MRI (Magnetic Resonance Imaging)
<="
RUAD!"B@D\DAD!" R S
B
#>S 2-3 B  "U
fMRI (Functional MRI) RBVD "B B""
B
(brain activity)
CV# B
< RD!
B
(#  oxygenated 
deoxygenated blood) D
 ) PET (Positron Emission Tomography)
<="
X=
 

B
R@D@
CV c BB 

D B# B
 BB 
RD!"#DW
B
@@
a
B
\#>SBB  B"  @
a
C@D
X=
 

B
"@
 U@
noD
X=
 
" (low activity)
D!
D

X=
 
V
(high activity)
C  

B
B X# B
D!"#DW
B

# B<  WD RD! BW


R!W!"B
@D@

 5 Mesolimbic dopamine pathway

( http:/www.drugabuse.gov/pubs/teaching/largegifs/slide-9.gif)

 6 Huntingtonts disease CRUA A MRI  PET

( http://neurosurgery.mgh.harvard.edu/pet-hp.htm)

 

  - (neuroanatomy and neurobiology) '()*+  
B
@
#> 3 @R@aA!
1.

 (hind brain) B""
 BU  U@ AAB R
 V=
2.

 (mid brain) "

V
R D   V
  V S"A"#V@^  B
" RU V@ 
 U@     !"B  @Bd!"
?@ #>
3.

 (fore brain) #>B
@"BABD<<B
#>@" RBT@
!"a
B
@W"
ABB XR A U
B B  
?
 U!"BC
ABA DAB


 7 B
@@
a

( http://news.bbc.co.uk/olmedia/360000/images/_363368_brain_parts300.gif)

SRB
B !" C?@ AB"<DD# #D@BR "<D
D# @DB C "<DD# @DBW @ synapse
D AB"<DD# #D@  synapse   neurotransmitter <="
BDU 
D@DU BCA
 
AB"@
 =
B"@
 @

neurotransmitter @ dopamine, serotonin, norepinephrine, GABA, glutamate,

endogenous opiods #>

 8 S synapse

(
http://pages.pomona.edu/~jbm04747/courses/fall2001/cs152/lectures/intro/synapse.jpg)
 ,-
.  '(/01
213  : 5
1/6
  1
2/01
2/137
(psychopharmacology of dependence for different substance classes)
D  @
#> 3 D@BR@a A! (1)
"^ _ 

B
(depressants) U@   D@B# /D
  (2) "^ _  

B
(stimulants) U@  CA  CAA 
  @B D (3) D#  (hallucinogens) U@ PCP LSD U
D  @DU B^ _@B
@

!"
BABB XR  brain receptor @
U 
D
RB

 B" =W !DD
?@DDa
@
?DR ^  B"@
 !W D 
B!"
BX=
?D RUR W "@
 @ "
=
" "B!RD@BWA!
 ^ _"B
@" @ mesolimbic pathway
<="
#> "A"R SB
 

 
" 2 
  /
!"
##

/ (>/?@A 1* 2@A '( '2 D(/@+ C*
/   ,-
. /@+ ) B2C*/01
2 C  
D(ethan •  "B?DW
•  !W  " XV • B?D#D"#D

ol) (inhibitory effect) 
DR \=W  

GABA D  #D"#D
DCA
 

B

• D?D  
  (receptor) CcR@
(excitatory effect) 
RB
prefrontal cortex; -
glutamate •  D D
R" U B   VDABA 
• ^ _ "  B
R<W ( #>D@R   (cognitive
reinforcing effect )  "    impairment)
"
   
!" @
#]€#b D# B (volume)
" mesolimbic #d T AD!"  
B
DD

dopamine pathway #>DB

D  # D
R" ABV
U
(delirium tremen)
D • R endogenous • !W@
 \ • AB

DD@B# inhibitory ^ _U (anti- (memory impairment)
 / (>/?@A 1* 2@A '( '2 D(/@+ C*
/   ,-
. /@+ ) B2C*/01
2 C  
(hypnotic neurotransmitters convulsant effect)
s and 
=W !"
 AB#D"
sedatives) #D

 RB

(brain receptor)
•  D @R 
 
D   
A
B@D R
@
!" #X=
B U
 "  CA  •   nicotinic •  !W 
W #] • B"?
(nicotine) cholinergic receptors ??D
  \=W D D @S
•  "B 
A    #D"#D

 V U" 
D D"

 RB
(brain @"?D
dopamine receptor)  
 CA @
• B!" # !" a


R V#
 V
   cc
@
B@
B@#>B   
D
V=  BV@
  R"D

D B=W
D@B ‚ƒ€ •   U" !"@ „mu… •  !W =W #D" •  #D"#D

(opioids) D …delta… opioids #D

 W
R W R opioid receptors
receptors. D  D peptides
 D@W BV@ BX=
 # RD • adaptations in
BRB
@""  @
R<DD reward, learning,

 
@ (adaptation in intracellular stress response
U@ mesolimbic signaling)
dopamine pathway • B!"  

D
CBW 
D W BVD  
!"
   "
#>A  #DB!W
U(cannabi •    •  !W =W @
 •  U
noids) cannabinoid \R^ _
@R@ B#>D@
 / (>/?@A 1* 2@A '( '2 D(/@+ C*
/   ,-
. /@+ ) B2C*/01
2 C  
D "B^ _
@ X T R AB@
dopamine R B 
B!"
   VR 
mesolimbic pathway cannabinoid D
#> R
B A ="
U "  \#b
 
U
U=W
CAA • 
 DV@<DD • @B !W@
c • ABA  AB#
(cocaine)
neurotransmitter U@ DR W ( cognitive deficit)
dopamine R @B@BD†# ‡" • AB? # R@c
dopamine  B!"B 
cortex
^ _=W @
 \B • AB? # 
B

@R " RU@R @AAB AD!"

@B <=Bd  
(depression) DB#‡   

UD

(ampheta •  "B D"

dopamine •  !W =W @
 • B#] !"
 
mine) #D#  \@^ _
W

@
 D (sleep
D
 =
D D^  B disturbance)  
D

dopamine V@<DD • B!"B @D !"
D neurotransmitter  <=Bd   
D • B #D"#D


!"a "" 
D V=@

  dopamine
RB

•   #D"#D
R
 ??D
@
 (regional
metabolic change)
• DS
D
ABA  (motor &
cognitive impairment)
 (ecstasy) •  "B D"
serotonin •  !W =W R
 • D  serotonin
DW
 =
DV@< •  B!"@R@ 
B

DD  <=Bd DB@ #V@ VB

D RAB


ABB XR 
 / (>/?@A 1* 2@A '( '2 D(/@+ C*
/   ,-
. /@+ ) B2C*/01
2 C  
 R  AAB

  

<=Bd 
  • B?D@ inhibitory • 
A W
  !W@R • B #D"#D
R
(inhalants) neurotransmitter  # B  " D 

U@ 
#  • RU@
 dopamine receptor
DD!" a BCB  U
@ • ABA    V
•   mesolimbic =W #
dopamine pathway •  #]
 # 

D#  • @D# S^ _@ •  !W =W @
 •  
 U" !W 

 brain receptor \ (acute or chronic

(hallucinogen) @D@
# • @B@B 
"  psychotic episodes)
U@ serotonin, B!"RU • 
A
B# D
glutamate D BRUB
acetylcholine

(>'(0,1
+>E31
2 
(neurobiological and biobehavioral basis of the development of substance dependence)
     ! " "#$% &" &
'$# %()  # " (* # 
"

1. 1
2 /I?/ E*+/+ * 6? 3
6J
(dependence as a learning process involving key brain region)
B!"ARUD V=X=
^ _R

 BR ^  BRU<WD
<W (highly rewarding and reinforcing effect)
   

   VRB
B!#>  =W
<="
RBC^  BRU<Wa @
 \B

^ _R

@
 B@B X @
R"^ _@ # Da (psychoactive substance)
=
B?DR ^  BW
B
  
U@ B" ?VB @RA=
 DDBRU
CRU " 
@
a" =WB!"B@ (withdrawal symptoms)
@B@B X @
RB@
##> D X T#BD
BB@
 D@WD @ RD#<W
 R "RABV"
DA A !""RUD@
W W
a " VX=
ABD DB-S
 
 "@R ^  B
DRU D@R@RU 
AD@W
D RD RUB@  ! 
DBRU<W
#]""
WBAB<<D#>?D @B @
#]
 R

U# D#]

AB

2. 1
2 /)1B5?0,1

(biobehavioral processes underlying dependence)
B
A  ‰ B!""UD"
 R@@
a
@

 

@ @
a !"RU V@  @
U@
 ""
 W  BAV@
<="
#>U!" V@ D
?@
BTW
 
RB
D"
 R ^  B!"RB#oB"

 \#> 
WU@ @  W 
B
R 
V
RR ^  B@
@!"

W
  =
#>?DB  D<<RU
#‡ B @
?D
@B

@""

V
RD B ? …   V…
""
ABB @
  DR (cues) "# R=WB

3. mesolimbic-dopamine pathway
B@/ ^ _@ # @DB^ _
SU @

@@R@^ _?@ mesolimbic-dopamine pathway
CBD ^ _@
=WU 
 mesolimbic-dopamine pathway
V@RB
@D
DU!"@#> ""
  @
B

 " A"
  @ ventral tegmental area ( VTA) <="
U!"B@
nucleus accumbens VTA #>B
@#" <DD# "B dopamine
#> neurotransmitter B
<DD# D@WU!"B @ 
B
""
 B ABA  AB
^  B""
 
?D#‡  @ nucleus accumbens
BABA"

V
RD   V
D@
ABA

V
RB!"B @
a"@
?D@
V
RR
^  B / ^ _@ # RB D"
dopamine  "B=WR 
nucleus accumbens <="
U!"@#>  A" BR AB
 

4. '5EC5'(6(/
0,1
 (motivation and incentive)

V
R D "
 B^  B  !"A"# @ 
D
#>A "A""
   @ mesolimbic-dopamine pathway
BAB"
   

V
R
B
RABA@ "A@ V@ 

V
R#>  ABRD^  B
@ "
 CA?DD
" BB
 "
@
 B#> R  
!W †
 A?DD" B
BU@ @
U@ X B@   B
\ ! D " (#> "
 B^ -
 B  ! incentive) B?DB@^  B
  (B@B
V
R) R

B
X    R@
BD^  B!"R B 
 "
X  BD
B@  D
 \@
B@@#> DCB !# U-  #>
 B!"R B
AB
 ^  B W+++
@
 
@ "
@
 B-
V
R <="

X=
AA@
 "
@
 B
D
V
RRB<="
 

?
S" 7
^  B

AB 

V
R" RB  +++
#>AB
 

<="

 (biological
 \B@B?D
#>  ^  B


 B" (B@B
B@B
V
R"R  B@B
biological needed)
B<="

 C# B
XV C "BABA@ V@ 
U  @
 W   D BAV@!"!
/ ^ _@ #  RDT
C " 
V
RRB
<WD<WD@DD@RB
R@
 WD "
@
a""
 W#>
" "#>@ 
U 
@

(biologically needed) B!"RU W <Wa
ABB @
 D "
""
 
B=W !"a
R  
" "B=WW
R^  BD ABR #  (behavioral &
neurochemical response)   W @ AB V=@ 
D (incentive
sensitization) <="

@
 D ""
 RU B?D@
V
RD^  B
?VRU "B=W !"
a B!"?@    V 
V
R"RU B XXV C "
DB AAD
X""
 RU R AB@
BB@BRD#RU<W
B@D BD\B "\#>A "@
R X T
@
B@B X 
@BB
D  
 BA" B DB@# ‡ X TD
@\
D#RUB!"#XV X @
a
RU@
U ="
DAB?  BBDU  
A\ 
@
A\B@  
W   !B@ 
=WAB@

@DAAD
<="

ABCB" 
@@
A
!"
B#] "
DBD B

'113 '13(?B

(13 1

2  6/@+ 5P556 2*06-B
(Genetic basis of individual differences in susceptibility to substance dependence)
B@RU@ !"

@"@ B (gene) ""

  
    #‡ B
 B (gene) Da  B#] "
DB
A"B  B (gene) "BC  
@@?V!" @ B genetic vulnerability to
substance B d=T? BRA A 
RD@B‚‚@RD‚‚@ADR D  B
!"V@#]
 BB
RR   
\d=T@@R
 B
(gene) ""
   U@ opiod receptor genes #>
BD†@B#]
 B"
R   " B B (gene)
""
 nicotine metabolism  nicotine RB
#>
U@    B B (gene) ""
 alcohol metabolism 
receptor 
GABA, serotonin, dopamine RB
#>
R@ B (gene) R"
   B"@

DB?D@#] "
DB@
 #>!W †A
A !"
B!R   c
 
D
^  B"B# CU@
 "

AB@
 BB?D@  RD U@
?D=
R RU  T
W
R !"
 RU  D?D@SR 
^ _
"@
R@DAADBRR"@    !W
 X T  "@
R@DAAD
W
@BABB!U#  (neurobiological commonalities)
@
  D #b
 UDaC A <="
#V@A  T@
RU V# D#o
"B!W

 W

/
236 1
2 R'( S 5
1/
(Comorbidity of substance dependence and mental illness)
BBB † 
  D #b
 U<="
B  @B
(comorbidity  ! dual diagnosis) #> !"
A"?#‡
V 
=
R@
 
?V  B @B
 ? # 
 RW 
 
# 

 !B@ B cWD
# \DBn]
?V#bV@DA W


An]
V@#>!CB@ @?V#bB 
 
=
B@@
@#
@
 U!" T CW c
D?V#‡ 
\n]
?V#bD@no
"d TDA 

U@W\B# ‡V@@a
BB †"
 @B @
   ? # 
  B
@#W
1. B!W†U# "B!
2.  RUU@D #b
 U !D?D
A
 RU
 2.  RU R  #b
 U !#V@ #D"
U 
<="
B
A# B! #b
 U
BD†BB †
W BW
@R"@ 
B?DR  ADC A  U@  CAA #>

\R  # D<="
#> ="

?V#bC A 

\R  #D"#D

 BW
A =A !W BABDW
<=Bd 
CcRU@
"  D@W\#> D
C A 
<="

@W
C A D"
 U#  (common
neurobiological substrates)
 d=TR †B @ B@ 50% 
?V#bC A  
B!"A"#   
6 %
 !C  R?V#bC A V
@A"# 4.5 @ " 
@
BAB"
@
SW

@
W@
U (C A D   )
 ABU
   BDU  (lifetime prevalence) @ 22%
RD@B?V#bC A  #  14% RA"#
 !C  R?V#bC A V
@A"# 2.3 @  d=TR †B B!" 20 Comment [U1]:  A
X?V#bC A    22%
#E"D @   C A <=Bd RU@
U  (lifetime rate of major depressive @A"#   14%
?V#bC A    1.57
disorder) RD@B?V  V
X=
38-44% #  7% RA" B@   D 80% @
A"#"A?  !VR? ?


A  B <=Bd  A  BCV
@A"# 3.3 @
"#>?V#b S (schizophrenia) R"A"#> SBCV
@A"# 3.8
@"  
A#bC A Cc SBCV
"RU "B!"A"#
 RU "V@RU@
26-88% =WC A @D# S #  20-30% RA"#
BABU!"BC
@
RDU  @
C A <=Bd  RU " R †B 
?VV "X=
60% B#  #b#>C A 
 #bC A <=Bd RD@BV "V
@D@BB@V 2 @  "
@W
?VV "<="
B#  <=Bd BC# AB \R D  "
A =
" =
" 
?V"B@A
B#  (14%  28%)    C A <=Bd RU@
U  32% RD@BR" UCAA
#  8-13% RD@B"B@RUCAA
AB? # @BRD@B?V#b S RU  #  D@A!
@?V#b SRU  # V
@A"# 2-5 @ DV
@C A # S!"a

W =
#>"U@  RUBAB"
AB\#b
 
B@B?D d=TBDR
# d D
BVD‰ B"U!"X!
(culture validity)
@  
#  B# CUW
@AB\#b
 UD  

??62'(U 6:
/@+ V )3
56 
 6?/2W2*5
- (treatment and
prevention: links with neuroscience and ethical issues)
  
#  #V@ ‰ TW

D^  B V#
RB@a <="

\# AB \ 
\
#>"XX
R# \  B
RW RU  
AAV@# ^  BX!#>  "?D"
 AXB="
" =WA! # B AB \
 @

 \
C WU
 !
@D
 D ABX"
 !# #D" RUB@R   X!@# AB \ !B@

1. / ??626X (type of treatment)

B  TW

D^  B V#@
aBB
R RU TRUD # ^ _
B@
R\
=
" U@
RUDB@R  "@R AB=
R  ! R  B@=
# 
AB!"RU
U@ naloxone, naltrexone #
opioid receptor R RD@B opiod ^ _B@
 ! disulfuram #
metabolism 
alcohol R  B@=
# 
AB!"RU
alcohol #]"A! ?V#bB@B X TABB@
B"


=
RRUB@@!"
(compliance) RBB@# AB \R 
D 
 ="
A!  RU"^ _AD
… ^ _@ # … "  @"RB@B?D@ @
  @
 CR(substitution therapy  ! maintenance therapy)
  WRUB D@BB nE opiod CRU codeine, methadone, buprenorpnine
!"D RU"? ŽBDD # U B D  U!WU
 U C A""
 RU (  RU\Bc @B)
B d=T BB"
@ methadone maintenance
?DR D  RU  CB@ ?DD@S (negative health
consequences) #  @
A"RU opiod Da<@a  ? ŽB
A"RU methadone @A"RU methadone
B!"XV
R ! !  TRC
DRUD@
B 
AB"@ DB   U!W HIV "@ # U B@
DBU !@
@
 \B   (*) \
A
#> !"
"
BC
(controversial)
BAB\B@D
 R# \"@#> ?   /  B !B@
"#D"R?V#bD   # S=
" @DB  # S="

B#>  \B @‚b"C

\UW
@ "R 
\ A=
X=
  B =
B@#D@R?V R "
"#> @
D
AB U@
# U B  !  
( U!W HIV)
R RU T"B?D@^ _
" "  ! R ^ _R

B
# \"A
   BA! ?V#b
  D B"  T
 RU immunotherapy U@
R  CAA@

B@B XDV@S#  (irreversible) C RU
cocaine specific antibody !"#o
B@RCAA?@V@B

\#># \="

" RR  B
B d=T @ # S@
aR" UR TBAB"
Da
pathway RB
<="
B?D@AB=
R D"
  B@
a
BT
=
RDAW

X=
?D@
a"BB RUD@W!" U@

 RU # #D"
 B (genetic modification)
"#V@ #D"#D
@
X (permanent change)
\X!#># \
  B"AU@
 
D
 
^  BCRUD ""
    V ?D
„ …
"^ _@B
\B D#RU
 C 

V
RD# #D"ABA  (motivational and cognitive therapy)
!"R 
V
RRB
U@" 
R
V
R
CUUR^  B!"  RU @
U@
   

!"!"R ^  B"# 
A (contingency management)
RUD R
"  B^  BU
 (positive reinforcement) D D
CT (punishment)
 !" R ^  B!" RU     TU
^  B- ABA 
(cognitive behavioral therapy U!"@ CBT) D #o
 <W (relapse prevention)
U@RA‰ABU!"BC
@
  
RB@@ "
 <="
B@"

 RUDAB A!    V B (unlearn)
""
^  B RUD#  V^  BRB@!"a"BB@
"A!RUD BB@
 B!" RDU# " R 
\RUD BWU  
 
" 3 !$%&&!'( !)
*!&&*&!+,$#/
!"
#
/
+C*'((>( ,-
. 
-
D(6X
/
‘C  • RU methadone ; synthetic opioids • Methadone maintenance
(heroine) agonist BAB#DSD?DU@R?V 
RU ‘C  D 
‚ƒ€Cc
B!"R 
^  BD RA#
=TD  !" a @B
• RU Buprenorphine ; partial agonist • B D^ _ @DBAB#D
" opioid receptor D#> weak SR RU
antagonist " kappa opioid receptor
• Levo-alpha-acetyl- • B D^ _  RU
3
methadol(LAAM): a synthetic opioid A W
/#R@?V 
• Naltrexone ^ _
morphine, •  RUW "BSD
W  X T"
heroine D opiod !"a C#>   SR VD
BAD 

antagonist " opiod receptor   (medically supervised

detoxification)   Naltrexone
B@U@ #o
 X T
R

BDR X T

BU=W RA"  
Naltrexone B@B?DR 
#]?V#bB@BRU

W AB \
 T =W 

BABB" @
?V#bD?V

B  RA# =T" ?D
D
R@R BVD!"RB RU@

B" B
 /
+C*'((>( ,-
. 
-
D(6X
/
CAA GBR 12909 ^CAA"
• • D

?  
AD  
(cocaine) mesolimbic dopamine neurone
RV DD <!WCAABRU 

(self administration)RD
rhesus
• Immunotherapy; RU antibody @ • V@R @
  
AD 
CAA #CAA
!"#o
B@RCAAV@B

  ( • A@aD# BD
AAV@# • ?D
Hypnotics/ ^  B
Sedatives)
 CA  • RU nicotine R V# ?@ ! • ?DR U@RA "
(nicotine) B‚ "
(nicotinine replacement AAV@# # UBX=
 
therapy)  " U@RA " \ B" =W
• Bupropion; weak norepinephine • U@R 
 " \ "BV
=W C
D dopamine reuptake inhibitor cB!"R @B nicotinine replacement
D#> nicotinic receptor blocker therapy
• Immunotherapy; A<"#o
B@R • V@R @
 ‰A<R" UR d=T
nicotine ^ _@B
 RBT  d=TRVR?D@R
  • Acamprosate • # ?V#b"  TD
D‘D(a #> 
A BCA
 
AD RS B ?V"  Acamprosate
lcohol) amino acid B?D T"@ @
U@n’“ nVS
<DDB
RDB   TA   
  \
"B# ( D"#D 
 B^ _
 RU @!"
#> 
DR<DB
V@RS
 hyperexicte)
• Naltrexone #> antagonist " opiod • U@D D#<W
receptor A
S
 DD# B !"B
• Disulfiram 
 ??D
• ?D TBAB@
aR@D d=T
acetaldehyde <="
#> metabolite 

alcohol  B"   acetaldehyde !"
B#] R !"
AB#>"
V
RD!R  B@@

# 
"RU@
B 
D
a =
RBABW
R"RU AB#>"
RU@
@!"

/
+C*'((>( ,-
. 
-
D(6X
/
alcohol
2. 5
-'(
56 2*
 C/@+  1
2 
(ethical issues in neuroscience research on substance dependence )
C"#D BDA B (moral principles) "
=X!R  
 
(biomedical research) @  A   _?V#b (respect of autonomy)
  BVDW
B""
  @BR T !  ABBA R
CB D
B B @B  / T
   ##o
R !"
ABDDAB#>@
R !"
BVD
?V#b/?V @BCA
   D "
A!
  
B@@R AB"
 ! @?V#b/?V @BCA
 (non maleficence
or do no harm) R

B
 "
"@R # CU@?V#b (positive
beneficence) B!"U"
WVD
B?D# CU  @
ABC BBWB@AB"
" @?V @BCA

   @W
# CU" 
B@AB"
" =W
W

=DRAB  B@?V#b/?V @B @
B (distributive
justice)
"A!
 W
AB"
D?D# CUR@?V#b/?V @B @
@B
(equitable distribution of risks & benefits)
RW  !"
"#># \ @
@"A  BVA A!
 A 

 B (genetic screening) <="
WBACCD BV@D"
@# \"
  @
AA!
BCV
B"?V"   A 

 B ?D  W
?D  \A! BAB? # ABU!"B"R

 (self esteem)
@BDD
D?D   "D  ?D@S
 

D?D# CU
 U@  T# B@ # U   V@BAB"

 T

B@
 A #‡ B@@


<="
ABD@WBC#>
V
B !"
RDa# d
 T# U B XX=
BVDS
?V#  B
!"R?V#

<\  BRX=
BVD@DA W
"# 
 3. 5
-'(/ YZ X
56 
 C/@+ 1
2
/01
2
(ethics and types of neuroscience research on substance dependence)
 d=T 
#  R !"
  /  BD# S
<="
@D# S\B# \  B
W " B!D@
  d=TD@W@
 D
R (animal experiments)   
  (epidemiological
research)  D
RA (human experimental studies)
D d=T#  V# T# S@
aRAD  ?V  (clinical trials
of therapies for substance dependence) <="
# ^ _
U @
a
D (placebo)  ! #  T U
^  B
C# B ?D T  V@B XD  !D
R VSS
 # 
AB DASU 
?V  
 d=T clinical trial B?D@ d=TU
D
(experimental study)

"?V @BBC# CU  @B   
W clinical trial
"
D!# U "BAB"
B @BR  
D
" "AA! T"RR  
RABU!"B"@ UR?D d=T@
B@"
#AB

!"R  B A B   B""

  RBT (human
research committee) ?V 
RB   B #‡  R d=T 
@BABXV
D#>#B" RCA
@
 d=T
C
R  R    
D@ (independent monitoring of
compliance with the study protocol) Cc 
?D
A
"  RU
D?V  ?VR

?D  SR 2 #E D
\BVDA 

?B'(
E*> B1[C*C)2V ? 2*-\B+/+ *

6?'*>PJ)1
2/01
2
(conclusion and implication for public health policy)

W #X=
ABR ABRX=
D
  @
B?D@ #D"#D
RB
D # @
 <="
  d=T RU@
10
#E"?@B
D
D@X=
# \
  B""
!"
AB VABR" "B=WW
<="
?V"
A 
 #‡  "UW
R CDDSVB SA
?D #]"   X!#>#]A@
 "

B@ D "

<="
#> "XVŽB\B@@
B"@R  VW
AAD
D@
AB 
WB  "D  RU "   D  U 

  ?DR#>C "A
 d=T
#    D  BAB#@
 \
B
AAB V"
B@A XBV 
@BVD"\B# CU@
BW
@  TR AAD
BW
 C !"#]
D@ CB
WA!

1. D  U DB @S =W  RU # B"RU
ABX"R RU   @
B@U 
/   
W

 @BR #]
=

AD
 
 "/ W @R =W
2. A  D  ?DD# 
W

 AB=
R^ _
 W
 
?DD@B!" (peer
pressure) D  

ABR RU(social context of their use)
B D
B@RA B# @ "
RU@=W DRUR# BV
=W
AB"
" \ "
V
=W
3.   =WW
D@B" DD@B"B@ R V#
   TcD
 RU  !  RU  (acute intoxiation, overdose) D RU U@
RU\Bc"B@ !"#]
D@

RBB  DCA
  " ?D"U@D D@W
4.   #>AB? # "BAB<< (complex disorder)
D
@B
R?V B@B XAAB

B#]""
W
 @
  B  R 
AB
‰ BD "
DB #] 
B@B  R" @
ARBAB"
@   W
@ "BDD
" "BD
5.  "B@B XD 

A=
X=
#]AB? # " =WB
#>?D" @B
 
!#B@
#"  ABB@
B" !
V
RR D 
@

   X!#>C A !W 
BDT#>aa
DB  @BS? # !" a @
D R
6. BS? # "  @B   U@  \#b
  
W
D?V 
=X=
AB\#b
 
 !?V#b
 \
=X=
 RU?  !  " @BR?V#b
B
B@S? # @B
\RA=
X=
D
? TD#o
 !""  "B?D
 RU
 
7. #oB T?V B@
A@RRU”
@ T
B  " #V@ #D"#D
^  B<="

d 

#  @ 
 R
AB (psychosocial intervention)
  (substitute psychotropic drugs)
<="
B X    T@
B #   S U@ TU 
 "BASU ?V ”DA A  BW
DS @
AB@
BdD
8. 
R?V
 D X=
 A
C
RB V#"B#   ?DR   S
W
@  #†BSVB (primary health care)
C?V#‡ 

R  "B#   SV

9.  "
A"
 V@ 
?V A!   (stigmatization)
D 
 (discrimination)
A" AB  BSA"   S
CB@B
!"@  D A@
BW
?V B  
 d=T C 

D DV@
ABB!A!"a
10.  D
R  #  
 =W@
@!"

D#V@  

ABd  (social science research)  #o

(prevention research)   (treatment research) D
 C (policy research) ?D  RUDD

 @B=W RUCDB  #]"=BVD d=T#>D
(evidence•based) <="
C
D@
B  D ?D #RU


  #]ACCD!"#o
D  D#]!"a""

@R # \
  D  B"@  R # \D@W
?V  SACA RABR" #W
R U DU @#
!"#>– #‡  " BBD#>#R d

 


World Health Organization. (2004). Neuroscience of psychoactive substance use and

dependence summary. Switzerland: Author.
  (Glossary)

  #>    V""

B
@A (dependence as a learning
process involving key brain region)
 BR ^  BRU<WD<W (highly rewarding and reinforcing effect)
"^ _@ #  (psychoactive substance)
 
@
a" =WB!" (withdrawal symptoms)
  BB  U^  B (biobehavioral processes underlying
dependence)
R (cues)
@
X=
AA@ABA
 @
a"@
?D@
V
R"^ -
 B (signaling the motivation value of stimuli)

V
RD 
D B^  B (motivation and incentive)
   !B@=W AB@

@DAAD (individual differences in susceptibility
to substance dependence)
AB@
 B (genetic vulnerability to substance)
‚‚@R (identical twin)
U#  (neurobiological commonalities)
  D #b
 U<=
" B  @B (comorbidity  ! dual diagnosis)
C A D"
 U#  (common neurobiological substrates)
 ABU
   BDU  (lifetime prevalence)
C A <=Bd RU@
U  (lifetime rate of major depressive disorder)
 S (schizophrenia)
BVD‰ B"U!"X! (culture validity)
 CR(substitution therapy  ! maintenance therapy)
?DD@S (negative health consequences)
C
(controversial)
B@B XDV@S#  (irreversible)
 # #D"
 B (genetic modification)
 #D"#D
@
X (permanent change)
 C 

V
RD# #D"ABA  (motivational and cognitive therapy)
   

!"!"R ^  B"# 
A (contingency management)
D R
"  B^  BU
 (positive reinforcement)
 D
CT (punishment)
   TU
^  B- ABA  (cognitive behavioral therapy U!"@ CBT)
 #o
 <W (relapse prevention)
ABU!"BC
@
  
RB@<="
B@"
 RUDAB
 (new stimulus-response associations that do not involve substance use or
craving)
   V B (unlearn)
 RUW B" SD
W  X T"  SR VD
BAD 

 (medically supervised detoxification)
<!WB T
 ""

" (self-administration)
DA B (moral principles)
  
  (biomedical research)
 A   _?V#b (respect of autonomy)
  
B@@R AB"
 ! @?V#b/?V @BCA
 (non maleficence
or do no harm)
 "
"@R # CU@?V#b (positive beneficence)
DRAB  B@?V#b/?V @B @
B (distributive justice)
 W
AB"
D?D# CUR@?V#b/?V @B @
@B (equitable
distribution of risks & benefits)
 A 

 B (genetic screening)
ABU!"B"R
(self-esteem)
 D
R (animal experiments)
  
  (epidemiological research)
 D
RA (human experimental studies)
 d=T#  V# T# S@
aRAD  ?V  (clinical trials of
therapies for substance dependence)
D (placebo)
A B   B""
  RBT (human research committee)
R  R    
D@ (independent monitoring of compliance with
the study protocol)

?DD@B!" (peer pressure)
 

ABR RU(social context of their use)
   TcD RU  !  RU  (acute intoxiation, overdose)
AB? # "BAB<< (complex disorder)
 
 R
AB (psychosocial intervention)
  (substitute psychotropic drugs)
  #†BSVB (primary health care)
  (stigmatization)
 
 (discrimination)

ABd (social science research)
 #o
 (prevention research)
  (treatment research)
 C (policy research)
=BVD d=T#>D (evidence•based)